Update on Approved Therapies for Dystrophic and Junctional Epidermolysis Bullosa. (PubMed, Pediatr Dermatol) - Sep 5, 2026 - "Since 2022, three therapies - birch triterpenes gel (Filsuvez), beremagene geperpavec-svdt (B-VEC, Vyjuvek), and prademagene zamikeracel (pz-cel, Zevaskyn) - have received regulatory approval, representing the first specific interventions for epidermolysis bullosa. Herein, we provide an overview on their mechanisms of action, efficacy, safety, and clinical implications."
Journal • Review • Dermatology • Gene Therapies
|
|
Alberto Pappalardo; Edward Eid; Lawrence F Eichenfield; Maria Gnarra Buethe; Rebecca C Olsen; Savannah E Bush
|